SNDL (SNDL) Q2 2025 Earnings Transcript

Delek reported Q2 adjusted EBITDA of $170.2 million, with refining EBITDA up $141 million sequentially and Logistics EBITDA at a record ~$120 million. Management raised its EOP run-rate target to $130 million-$170 million from $120 million and reiterated DKL 2025 EBITDA guidance of $480 million-$520 million, while recording $16 million of dividends and $13 million of buybacks. Offsetting the operational progress, the company posted a GAAP net loss of $106 million and continues to face unresolved SRE regulatory risk.

Analysis

DK is starting to look less like a simple cyclical refiner and more like a self-help + structural separation story. The market should care less about the headline loss and more about the fact that the incremental margin capture is being driven by controllable levers: throughput reliability, product slate optimization, and commercial contract repricing. That matters because these gains are happening while benchmark conditions remain mediocre, which implies the next leg is less dependent on a crude beta rebound and more on execution compounding into 2H cash flow.

The most important second-order effect is that DKL’s liquidity and asset buildout reduce holdco overhang at exactly the moment the midstream asset base is becoming more self-funding. A cleaner DKL can support a higher multiple for the logistics stake, but it also changes the equity story for DK: more of the value is migrating into separable buckets, which can unlock valuation if management keeps monetizing third-party EBITDA. The flip side is that the capital intensity of Libby 2 and other growth projects creates a near-term drag on visible free cash flow, so the equity may not rerate cleanly until investors believe the spend is behind them.

Regulatory optionality is the swing factor and it cuts both ways. If SRE relief lands, the earnings power step-up could be large enough to re-rate the stock materially because it would convert a policy overhang into recurring cash flow; if delayed or denied, the stock remains a levered claim on operational improvement rather than a clean policy win. The key contrarian point is that consensus may be underestimating how much of the quarter was internally manufactured versus cyclical—meaning the downside in a softer crack environment is cushioned, but the upside from an eventual SRE or DKL separation catalyst could be outsized over the next 3-9 months.

Key Decisions for Investors

• Long DK vs. a pure refinery basket (e.g., short VLO or PBF) for 3-6 months: DK has a stronger self-help catalyst stack and embedded DKL optionality; risk is higher capex and regulatory slippage.
• Buy DK common on pullbacks below recent post-earnings support and pair with a small short in DKL units if the spread widens excessively: thesis is holdco valuation catch-up as separation progresses; risk is DKL multiple expansion outpaces DK.
• Use upside calls on DK with 3-6 month tenor rather than stock if positioning for an SRE headline: convex payoff if EPA action hits, limited premium at risk if timing slips.
• Avoid chasing the name after strong refinery crack days; entry is better on crack compression because the market is likely underpricing the self-help engine and overpricing spot margin beta.
• Monitor for a catalyst window around the next regulatory decision and 3Q guidance update; if no SRE progress appears, trim by 25-50% because the equity then trades more on execution alone than on a binary legal outcome.